Amgen Inc.'s $2.7 billion deal with BeiGene Ltd. could signal an increase in partnerships with Chinese companies.
Amgen Inc.'s $2.7 billion licensing and cancer research deal with BeiGene Ltd. may be a wake-up call for other U.S. pharmaceutical companies to seek new partnerships in China to gain a foothold in the emerging market.
"[The U.S.] healthcare sector is maturing, and we're trying to spend less on drugs in our country," Brad Loncar, biotech investor and CEO of Loncar Investments, said in an interview. "China is where a big portion of the future growth of our industry is, and I think that's starting to dawn on all companies."
Amgen picked up a 20.5% stake in BeiGene, under which three of Amgen's drugs will be sold in China for at least five years. The two will also work to develop drugs in the California company's pipeline.
For Amgen, which has suffered under the weight of competitive generics and biosimilars of its once-profitable drugs, reaching into China's growth market gives the company a chance to gain a foothold while drug prices are at risk in the U.S.
Franck Le Deu, a Hong Kong-based senior partner at the McKinsey & Co. management consulting firm, told S&P Global Market Intelligence that the Amgen-BeiGene move would spur more companies to consider aligning with Chinese biotechs.
"Ultimately, companies have to determine if a go-alone strategy, with some partnerships, is the way to go, or if a bigger structural move is needed to effectively compete in the China market," Le Deu said. "Similarly, emerging Chinese biotechs are likely to pursue strategic collaborations with multinationals more purposefully — all of this should feed a fertile ground for business development."
Amgen-BeiGene deal an awakening for US pharma seeking space in Chinese market
Chart of the week
Healthcare stocks led a record-setting S&P 500 in October as earnings surprised
The U.S. Department of Health and Human Services is suing Gilead Sciences for infringement of government patents on medicines used to prevent HIV.
US government sues Gilead claiming HIV prevention drugs infringe CDC patents
Gilead Sciences Inc.'s HIV prevention drugs Truvada and Descovy infringe government patents, the Trump administration is alleging in a new lawsuit.
AstraZeneca to accelerate drug launches in China as approval times get shorter
AstraZeneca PLC plans to release about 55 new drugs in China in the next five years, compared with about 30 innovative drugs in China over 26 years, said Mike Lai, the company's country general manager.
AstraZeneca to set up $1B China fund and open research, technology centers
The fund marks AstraZeneca's first foray into healthcare investments and is being established to support companies and foster innovation in China's healthcare system.
Animal health companies look to poultry, pets after Q3 swine fever losses
Animal health companies Zoetis Inc. and Elanco Animal Health Inc. continued to report millions of dollars in losses from African swine fever impacts in Asia, but noted improvements were seen in poultry and pets.
Medicare agency delays price transparency, finalizes 340B payment cuts
The Centers for Medicare and Medicaid Services delayed finalizing its hospital price transparency provision in a Nov. 1 finalized rule. But the agency moved forward on two provisions that have previously been struck down in federal court.
Senate health committee sets hearing to vet Trump US FDA nominee Hahn
Stephen Hahn, President Donald Trump's nominee to lead the U.S. Food and Drug Administration, will go before the Senate health committee Nov. 20 ahead of the candidate's confirmation vote.
In other news
China's CanSino Biologics eyes increasing access of its Ebola vaccine in Africa
The Tianjin, China-based company is eyeing expanding the use of the vaccine to the local population in disease outbreak areas and neighboring countries, CEO Yu Xuefeng said.
White House budget office vets rule to permit importation of foreign drugs
A proposed rule that would permit U.S. states to import prescription drugs from Canada and other foreign nations is now under review at the White House Office of Management and Budget, though there is no timeline for its release.
Stryker to acquire Wright Medical for $4B
Stryker Corp. agreed to acquire Wright Medical Group NV, a device company focused on implants for extremities, for $30.75 per share.
Future of Kentucky's Medicaid program at stake in governor's race
Medicaid could be a deciding factor in the state's Nov. 5 gubernatorial election, which pits a Republican incumbent advocating for restrictions to the health insurance program against a Democrat seeking to preserve an expansion of coverage.
ObsEva stock dives 63% as drug fails to increase IVF pregnancy rate
ObsEva SA will discontinue the development of its medicine nolasiban in an in vitro fertilization program after the drug failed to increase the rate of pregnancy compared to placebo in a late-stage study.
Essential Healthcare is a weekly collection of critical developments across the pharmaceutical, biotechnology, healthcare provider, healthcare technology and medical equipment industries that draws on exclusive analysis and value-added content from the Healthcare News team at S&P Global Market Intelligence. Subscribe now to get Essential Healthcare delivered to your inbox every week.